Dr. Hadjipanayis is a Professor of Neurosurgery and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. He serves as Chair of Neurosurgery at Mount Sinai Downtown Union Square/Beth Israel and Director of Neurosurgical Oncology for the Mount Sinai Health System.
He is a board-certified neurosurgeon who has devoted his entire career to the treatment of brain tumor patients.
He is Director of the Mount Sinai Brain Tumor Nanotechnology Laboratory in the Tisch Cancer Institute where he studies novel therapeutics targeting glioblastoma (GBM). His team is very active in preclinical and translational studies glioma models.
His Ph.D. graduate training in Biochemistry and Molecular Genetics at the University of Pittsburgh, during his neurosurgery residency, focused on viral gene therapy of GBM.
Dr. Hadjipanayis has been a tireless brain tumor advocate leading the nonprofit Southeastern Brain Tumor Foundation (SBTF) in the past. He has been the PI of multiple clinical trials and a PI of university-, private foundation-, and NIH-funded grants focused on gliomas.
He is the Sponsor and IND holder of a multicenter Phase II study involving the use of 5-ALA (Gliolan) and fluorescence-guided surgery (FGS) for the resection of new or recurrent high-grade gliomas.
He was the first to use Gliolan and perform FGS on a glioma patient in the US in 2011. He also helped lead the effort for FDA approval of 5-ALA (Gleolan) in the US for use during glioma surgery in June 2017.
Friday, July 26, 2019 at 12:00pm to 1:00pm
Wallace Tumor Institute, 101
1824 6th Avenue South, Birmingham, AL 35233